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Abstract
Background: Cyclin D1 and p16 are involved in the regulation of G1 checkpoint and may play an
important role in the tumorigenesis of nasopharyngeal carcinoma (NPC). Previous studies have
examined the level of expression of cyclin D1 and p16 in primary untreated NPC but no such
information is available for recurrent NPC. We set out in this study to examine the expression
level of cyclin D1 and p16 in recurrent NPC that have failed previous treatment with radiation +/chemotherapy.
Patients and methods: A total of 42 patients underwent salvage nasopharyngectomy from 1984
to 2001 for recurrent NPC after treatment failure with radiation +/- chemotherapy. Twenty-seven
pathologic specimens were available for immunohistochemical study using antibodies against cyclin
D1 and p16.
Results: Positive expression of cyclin D1 was observed in 7 of 27 recurrent NPC specimens (26%)
while positive p16 expression was seen in only 1 of 27 recurrent NPC (4%).
Conclusion: While the level of expression of cyclin D1 in recurrent NPC was similar to that of
previously untreated head and neck cancer, the level of p16 expression in recurrent NPC samples
was much lower than that reported for previously untreated cancer. The finding that almost all
(96%) of the recurrent NPC lack expression of p16 suggested that loss of p16 may confer a survival
advantage by making cancer cells more resistant to conventional treatment with radiation +/chemotherapy. Further research is warranted to investigate the clinical use of p16 both as a
prognostic marker and as a potential therapeutic target.

Background
Nasopharyngeal carcinoma (NPC) is a prevalent malignancy in Southeast Asia with reported incidence rate ranging from 10 to 53 cases per 100,000 persons per year [1].
Although it is a relatively uncommon cancer in western

countries with an incidence rate of less than 1 case per
100,000, it poses a significant health problem in regions
of the US where there is large population of Asians. External beam radiation therapy is considered the primary
mode of treatment for previously untreated NPC. This is
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mainly due to the high degree of sensitivity of this tumor
to radiation as well as the anatomic constraints for surgical access in this highly complex region. Despite advances
in diagnostic and treatment modalities, loco-regional failure is still significant with reported rates of 15.6% to 58%
[1,2]. The addition of chemotherapy concurrent with radiation has been shown to improve survival in patients with
NPC
[3].
Although the molecular events responsible for the pathogenesis of NPC remain to be elucidated, the final common pathway appears to be a disruption of the
mechanisms involved in the regulation of cell cycle progression, leading to uncontrolled cell proliferation. The
most critical point in cell cycle regulation is the G1 checkpoint. It is here that complex interactions take place to
determine whether the cell will exit the cell cycle and go
into a quiescent state (G0) or enter into the S phase and
proceed with cell division [4]. These complex interactions
involve a large number of regulatory proteins such as cyclins, cyclin-dependent kinases (CDKs), and CDK-inhibitors. Among the cyclins involved in G1 phase, cyclin D1
appears to be most strongly implicated in human carcinogenesis. Cyclin D1, through its interaction with cyclindependent kinase-4 or 6 (CDK-4/6), forms a complex that
inactivates the tumor suppressor protein retinoblastoma
(pRb) through phosphorylation [4]. Phosphorylation of
pRb releases transcription factors such as E2Fs which then
activate a series of events that allow entry into S-phase and
cell division [4]. An increased level of cyclin D1 expression has been reported in a number of malignancies [5]
including esophageal, ovarian, breast, uterine, colon,
lung, prostate, lymphoma, as well as head and neck cancers. Between 30% to 83% of head and neck squamous
cell carcinoma (HNSCC) were reported to be associated
with cyclin D1 over-expression [6,7]. The progression of
cells from G1 to S phase, on the other hand, is blocked by
a potent tumor suppressor protein, p16, which acts to disrupt the cyclin D1/CDK-4/6 complex. Deletions, mutations, or methylation of the p16 gene has been implicated
in the development of a variety of human malignancies,
including head and neck cancer [6,8].
The disruption of the "Retinoblastoma/cyclin D1/p16
pathway" involved in the regulation of the G1 checkpoint
also appears to play an important role in the tumorigenesis of NPC. Over-expression of cyclin D1 and/or loss of
p16 has been reported in several studies on NPC. These
studies found an increased level of cyclin D1 expression in
30% [7] to 66% [9] and the lack of expression of p16 in
40% to 70% of previously untreated NPC specimens [912].
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knowledge, no previous studies have been reported on the
expression level of these proteins in recurrent HNSCC. We
set out in this study to examine the expression level of cyclin D1 and p16 in recurrent NPC that have failed previous
treatment with radiation +/- chemotherapy.

Methods
Patients
A total of 42 patients underwent salvage nasopharyngectomy by one of the investigators (WEF) at Stanford University Medical Center from 1984 to 2001 for recurrent
NPC after treatment failure with radiation +/- chemotherapy. The clinical, demographic, and results of salvage
nasopharyngectomy on the first 37 patients have been
published previously [13]. Between 2000 and 2001, 5
additional patients underwent nasopharyngectomy,
bringing the total number of patients to 42. A search
through the archival tissue bank at Stanford Medical
Center identified 27 pathologic specimens which were
available for immunohistochemical study using antibodies against cyclin D1 and p16. The other 15 specimens
were unavailable for this study due to exhaustion of the
limited amount of pathological specimen during the original pathologic diagnosis.

The surgical approach for the salvage nasopharyngectomy
depended on the location of the tumor but included
intraoral, transpalatal, and sublabial transmaxillary
approaches. Isolation of the internal carotid artery and
cranial nerves IX, X, and XII to the skull base was performed. Tumors were removed en bloc when possible.
Any recurrent neck disease was addressed with a neck dissection. There was no evidence of distant metastasis in any
of these study patients. At the time of salvage surgery, 20
patients have previously been treated with 1 course of
radiation, 2 patients with 2 courses of radiation, 2 patients
with 2 courses of radiation plus chemotherapy, and 3
patients with a single course of radiation plus chemotherapy.
Tissue specimens
The formalin-fixed, paraffin-embedded surgical specimens removed from these 27 patients were used for this
study. Tissue blocks from the surgical margin were
selected in order to include both the normal and cancer
tissues in the same slide. The blocks were sectioned at 5
μm and mounted on poly-L-Lysine coated slides. The sections were stained with H&E and reviewed by a single
pathologist (GJB) to confirm the diagnosis of NPC. Most
of the specimens were classified as undifferentiated
(WHO III) and poorly differentiated NPC (WHO II) (Figure 1, Panel A and B).

Although a large body of data exists on cyclin D1 and p16
expressions in HNSCC including NPC, to the best our
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Analysis of level of expression
Immunostaining of cyclin D1 and p16 was evaluated by a
board-certified pathologist (GJB). Ten high power fields
were successively examined using standard light microscopy. Cytoplasmic reactivity was disregarded as nonspecific and only staining of tumor nuclei was scored as
positive. A specimen was scored as negative or no staining
(0) when < 5% of the tumor cells exhibited nuclear staining. A specimen was considered positive when > 5% of the
tumor cells exhibited nuclear staining. The 5% cut-off for
positivity was chosen in order to be consistent with other
similar studies on p16 and cyclin D immunostaining in
the literature. Non-uniform staining of p16 and cyclin D1
was expected since the expression of these 2 proteins in a
particular tumor cell is dependent on the phase of cell
cycle with a peak expression in G1 phase. The intensity of
the positive immunostains were then graded semi-quantitatively as 1+ (positive/weak staining), 2+ (positive/moderate staining), and 3+ (positive/strong staining)
(additional file 1).
Statistical analysis
Overall disease-free survival was calculated using the Kaplan-Meier program from SPSS 14.0 for Windows (SPSS,
Chicago, IL). Significance in survival outcome between
different groups of patients in this study population was
analyzed by the Log-rank test (Mantel-Cox).

Figure
Panel
noma
A:
(H&E
1Lymphoepithelioma
× 400)
type of nasopharyngeal carciPanel A: Lymphoepithelioma type of nasopharyngeal carcinoma (H&E × 400); Panel B: Poorly differentiated nasopharyngeal carcinoma (H&E × 400); Panel C: Grade 0 staining for
Cyclin D1 (× 400); Panel D: Grade 0 staining for p16; Panel E:
Grade 3+ staining for Cyclin D1 (× 400); Panel F: Grade 3+
staining for p16 (× 400)

Immunohistochemistry for cyclin D1 and p16
Using the Biogenex i1000, deparaffinization and microwave antigen retrieval were performed on the tissue sections. This was followed by immunostaining using the
Dako Autostainer. Briefly, the slides were incubated in
0.3% hydrogen peroxide and blocked using a non-serum
based blocking agent. The slides were then incubated with
primary monoclonal mouse anti-cyclin D1 antibody
(dilution 1:25; Zymed, South San Francisco, CA) and
monoclonal anti-p16 antibody (F-12) (dilution 1:40;
Santa Cruz Biotechnology, Santa Cruz, CA) for 60 minutes at room temperature. Following the primary incubation, the slides were incubated with biotinylated goat antimouse antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) for 10 minutes followed by incubation with strepavidin-peroxidase reagent for 10 minutes. Finally, the slides
were visualized using DAB and counterstained with
Mayer's hematoxylin.

Results
Twenty-seven recurrent NPC specimens were examined in
this study. The average age at the time of salvage nasopharyngectomy was 51 years (range, 27 to 72 years). There
were 18 men and 9 women. Thirteen patients were Asian
and 14 were non-Asians. Patients were restaged using the
1998 AJC Cancer Staging Manual and 16 were staged as
recurrent (r)T1, 2 as rT2, 5 as rT3, and 4 as rT4. Other relevant clinicopathological characteristics of these patients
were shown in additional file 1.
The results of the immunohistochemical staining of these
27 recurrent NPC specimens were presented on additional
file 1. Cyclin D1 over-expression was limited to tumor
cells and no immunostaining was noted on the surrounding normal epithelium of the nasopharynx. Thus, the normal epithelium served as internal negative control. On the
other hand, normal tissue stained positive for p16 and
was used as internal positive control. Representative samples of cyclin D1 and p16 immunostaining were shown in
Figure 1. Absence of staining for cyclin D1 and p16 were
illustrated in panel C and D respectively. In Panel E and F,
3+ immunostaining was demonstrated for cyclin D1 and
p16 respectively. Of the 27 recurrent NPC specimens, 7
(26%) stained positive for cyclin D1 proteins while only
1 (4%) demonstrated immunostaining for p16. Of the 7
specimens that stained positive for cyclin D1 protein, 1
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stained strongly (3+), 3 stained moderately (2+), and 3
stained weakly (1+).

Kaplan-Meier Survival Curve

Discussion
In this study, we examined the expression level of cyclin
D1 and p16 in recurrent NPC that have failed previous
treatment with radiation +/- chemotherapy. These specimens were procured at the time of salvage nasopharyngectomy. We found over-expression of cyclin D1 in 26% and
the lack of expression of p16 in 96% of recurrent NPC
specimens. While the level of over-expression of cyclin D1
(26%) in recurrent NPC specimens was similar to the levels of over-expression (30%[7] to 66%[9]) found in primary untreated NPC, the lack of expression of p16 in
recurrent NPC specimens (96%) was significantly higher

Figuresalvage
Kaplan-Meier
lowing
2
analysis
nasopharyngectomy
showing the disease-free survival folKaplan-Meier analysis showing the disease-free survival following salvage nasopharyngectomy. The 5-year disease free
survival was 50%.

1.0

0.8

Cum Survival

Length of follow-up ranged from 5 months to 164
months, with mean of 45 months. Four patients were lost
to follow-up and were not included in the survival analysis. At the time of last contact, patients were classified as
no evidence of disease (NED), alive with disease (AWD),
or died of disease (DOD). The 5-year disease-free survival
following salvage nasopharyngectomy for the 23 patients
(excluding the 4 patients that were lost to follow-up) was
50% (Figure 2). Using the Log-rank test, no statistical significance in disease-free survival was found to correlate
with variables such as gender, staining with cyclin D1
(Figure 3), staining with p16, WHO classification (Figure
4), or recurrent stage (Figure 5). However, there was a statistically significant difference (p = 0.003) in 5-year disease-free survival between Asian (88.9%) and non-Asian
patients (22.2%) (Figure 6).

Positive staining with cyclin D1
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D1
Figure
and patients
3whoseanalysis
tumor
whoseshowing
specimens
tumor specimens
thestained
disease-free
positive
stained
survival
negative
for cyclin
of
Kaplan-Meier analysis showing the disease-free survival of
patients whose tumor specimens stained positive for cyclin
D1 and patients whose tumor specimens stained negative.
Based on Log-rank test, there was no statistically significant
difference in disease-free survival between these 2 groups
based on cyclin D1 expression (p = 0.518).

than those typically reported for primary untreated NPC
(40% to 70%) [9-12].
There are a number of studies that attempted to correlate
the level of expression of cyclin D1 and p16 in cancer with
prognosis. Several investigators reported association
between over-expression of the proto-oncogene cyclin D1
with worse prognosis in terms of shorter survival and
increased incidence of recurrence [14-16]. This poor prognosis in tumors over-expressing cyclin D1 was found to be
independent of other clinicopathological parameters such
as tumor stage, nodal or distant metastasis, or degree of
differentiation [14-16]. Other studies however either
failed to show this association between over-expression of
cyclin D1 and poor clinical outcome [17] or found a
reverse association between over-expression of cyclin D1
and poor prognosis. In a series of 65 patients, Hwang et al
[9] reported that loss of cyclin D1 was closely related to
local recurrence after radiation therapy for NPC. Our data
also failed to support the association between overexpression of cyclin D1 with increased risk of recurrence.
If over-expression of cyclin D1 was associated with
increased risk of recurrence, we would expect to find a
higher proportion of recurrent NPC specimens to overexpress cyclin D1 compared to previously untreated NPC.
However, the level of over-expression of cyclin D1 in
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Figure 4basedanalysis
Kaplan-Meier
patients
on the WHO
showingclassification
the disease-free survival of
Kaplan-Meier analysis showing the disease-free survival of
patients based on the WHO classification. There was no statistically significant difference in disease-free survival among
these groups of patients (p = 0.243).

Figure
Kaplan-Meier
Asian
(A)
6 versus
analysis
non-Asian
showing
(NA)
thepatients
disease-free survival of
Kaplan-Meier analysis showing the disease-free survival of
Asian (A) versus non-Asian (NA) patients. There was a statistically significant difference in the 5-year disease-free survival
between Asian patients (88.9%) and non-Asian patients
(22.2%) with p = 0.003 based on the Log-rank test.

Kaplan-Meier Survival Curve

recurrent NPC specimens found in this study (26%) was
not higher, but slightly lower than those reported for previously untreated NPC (30% to 66%) [7,9,18].

1.0

Cum Survival

0.8
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0.6
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0.4

Stage 3
Stage 4
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Figure
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survival
nasophaof
Kaplan-Meier analysis showing the disease-free survival of
patients based on the staging at the time of salvage nasopharyngectomy. There was no statistically significant difference
in disease-free survival among these 4 groups of patients (p =
0.347).

The other interesting finding from this study was the lack
of p16 expression in almost all (96%) of the recurrent
NPC specimens. This was in contrast to the 40% to 70%
reported rate of p16 loss in previously untreated NPC
(table 1). This high proportion of recurrent cancer with
loss of p16 activity suggested that p16 loss may confer survival advantage by making these cancer cells more resistant than their p16 positive counterparts to conventional
treatment with radiation +/- chemotherapy. Other investigators have also reported on the association between loss
of p16 expression and worse prognosis. Hwang et al [9]
reported on a statistically significant correlation (p =
0.047) between absence of p16 expression with higher
rate of local recurrence in NPC. In another study involving
84 NPC samples, Makitie et al [12] found a statistically
significant association (p = 0.022) between absence of
p16 expression and inferior overall survival rate. The
absence of p16 expression found in nearly all of our recurrent NPC samples in this study seemed to corroborate the
finding of these investigators. Taken together, these findings would suggest that the loss of p16 tumor suppressor
proteins in NPC may confer resistance to radiotherapy
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Table 1: Four different studies showing that between 40% to 70% of previously untreated NPC specimens have loss of p16 expression.

Investigators

Number of NPC specimens examined

Percent of NPC with loss of p16 staining

Hwang et al [13]
Makitie et al [16]
Huang et al [15]
Baba et al [14]
Lin et al [this study]

65
84
74
20
27

65%
70%
42%
40%
96%

This is in contrast to the 96% of recurrent NPC found in this study to have loss of p16 expression.

and may be associated with higher rate of failure after
therapy with radiation +/- chemotherapy.

recurrent NPC specimen available for immunohistochemical study difficult.

Finally, it is interesting to note that Asian patients, following treatment with salvage nasopharyngectomy, have a
statistically significant better 5-year disease-free survival
compared to Caucasians and Hispanics (p = 0.003) (Figure 5). The reason for this difference is unclear. The Asian
and non-Asian group did not differ significantly in their
level of cyclin D1 expression. Four out of 13 Asians and 3
out of 14 non-Asians stained positive for cyclin D1.

Conclusion

Although this is the first study looking at the expression
levels of cyclin D1 and p16 in recurrent NPC, this study
has several limitations. First, pre-irradiated NPC specimen
were not available for use as control due to the fact that
most of these patients were referred from outside institutions (in many cases, from institutions outside of US)
after treatment failure with radiation therapy. The unavailability of pre-irradiated NPC specimen raised the issue
of whether the lack of expression of p16 in these recurrent
NPC samples was pre-existing (pre-treatment) or the
result of selection pressure from treatment. The data presented in this study will not be able to answer this question. Our assumption here was that these recurrent
tumors would have the same staining characteristics
showing absence of p16 expression even before treatment
with radiation. Irrespective of whether the p16 expression
was lost during tumor transformation (before treatment)
or during treatment with radiation, this marked reduction
of p16 in recurrent NPC specimen underscored the importance of p16 alteration in NPC and provided support for
therapeutic strategies that aim to restore p16 expression.
There have been pre-clinical studies which demonstrated
the ability of exogenously introduced p16 to inhibit proliferation and induce apoptosis in NPC cell culture [19].
Another limitation of this study was the small number of
cases (n = 27) examined. However, both the low prevalence of NPC in the US and the reluctance of most head
and neck surgeons to surgically salvage recurrent NPC
made access to a large number of surgically removed

In this study, we have determined the level of expression
of cyclin D1 and p16 in recurrent NPC that have failed primary treatment with radiation +/- chemotherapy. While
the level of expression of cyclin D1 in recurrent NPC was
similar to that of previously untreated HNSCC, almost all
of the recurrent NPC samples lacked expression of p16
protein. This finding suggested that the loss of p16 tumor
suppressor protein in NPC may be associated with higher
rate of failure after treatment with radiation +/- chemotherapy. Thus, p16 expression level appeared to be a clinically useful prognostic marker in NPC and warranted
further investigations. Further, therapeutic strategies targeting the p16 pathway may be a promising approach to
improve the treatment outcome of NPC. Several promising studies have demonstrated the ability of exogenously
introduced p16 to inhibit proliferation and induce apoptosis in NPC cell culture [19].
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